Our results indicated that the expression level of HIC1 is associated with TMB in 20 cancer types and MSI in 5 cancer types, such as STAD, READ, SKCM, and DLBC, suggesting the promising potential of HIC1 as a biomarker for predicting the efficacy of cancer immunotherapy. This evidence concerns the gene HIC1 and cancer.